Companies
StartEngine
able to raise under the larger Regulation A+ exemption (up to $75 million) in addition to Reg CF, has hosted campaigns for Eliaz Therapeutics and Frontier Bio, a developer of lab-grown human tissue models and tissue-engineered vascular grafts intended as safer preclinical alternatives to animal studies.
- Country
- United States
reg-a-plus
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| finance-investment | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $3 million target (Reg CF) (2026-06-11) | investcf.eliaztherapeutics.com · globenewswire.com |
| Funding | $8 million total raised to date (2026-06-11) | globenewswire.com |
| Headcount | 10 individuals (employees and contractors) (2026-04-29) | sec.gov |
| Revenue | $302,481 (2025-12-31) | sec.gov |
| Regulatory approval | FDA Breakthrough Device Designation awarded (2025-01-01) | eliaztherapeutics.com · invest.eliaztherapeutics.com · globenewswire.com · startengine.com |
| Headquarters | Santa Rosa, California, United States | sec.gov |
Independent sources: eliaztherapeutics.com · globenewswire.com · invest.eliaztherapeutics.com · investcf.eliaztherapeutics.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Crowdfunding & retail investment in biotech | finance-investment | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.